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Abstract 
Background: The MitraClip procedure was established as a therapeutic alternative to mitral 
valve surgery for symptomatic patients with severe mitral regurgitation (MR) at prohibitive 
surgical risk. In this study, the aim was to evaluate 5-year outcomes after MitraClip. 
Methods:  Consecutive patients undergoing the MitraClip system were prospectively 
included. All patients underwent clinical follow-up and transthoracic echocardiography.  
Results: Two hundred sixty-five patients (age: 81.4 ± 8.1 years, 46.7% female, logistic 
EuroSCORE: 19.7 ± 16.7%) with symptomatic MR (60.5% secondary MR [sMR]). Although 
high procedural success of 91.3% was found, patients with primary MR (pMR) had a higher 
rate of procedural failure (sMR: 3.1%, pMR: 8.6%; p = 0.04). Five years after the MitraClip 
procedure, the majority of patients presented with reduced symptoms and improved functional 
capacity (functional NYHA class: p = 0.0001; 6 minutes walking test: p = 0.04). Sustained 
MR reduction (≤ grade 2) was found in 74% of patients, and right ventricular (RV) function 
was significantly increased (p = 0.03). Systolic pulmonary artery pressure (sPAP) was 
significantly reduced during follow-up only in sMR patients (p = 0.05, p = 0.3). Despite a 
pronounced clinical and echocardiographical amelioration and low interventional failure, 5-
year mortality was significantly higher in patients with sMR (p = 0.05). The baseline level of 
creatinine (HR: 0.695), sPAP (HR: 0.96) and mean mitral valve gradient (MVG) (HR: 0.82) 
were found to be independent predictors for poor functional outcome and mortality.  
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Conclusions: Transcatheter mitral valve repair with the MitraClip system showed low 
complication rates and sustained MR reduction with improved RV function and sPAP 5 years 
after the procedure was found in all patients, predominantly in patients with sMR. Despite 
pronounced functional amelioration with low procedure failure, sMR patients had higher 5-
year mortality and worse outcomes. Baseline creatinine, MVG, and sPAP were found to be 
independent predictors of poor functional outcomes and 5-year mortality. 
Key words: MitraClip, transcatheter mitral valve repair, long-term outcomes, mitral 
regurgitation 
 
 
INTRODUCTION 
Mitral regurgitation (MR) is the second most frequent valve disease, with an 
increasing prevalence in elderly (> 75 years) patients, and is related to reduced functional 
capacity and impaired quality of life. Transcatheter mitral valve repair (TMVR) with the 
MitraClip system (Abbot Vascular, Inc., Santa Clara, California) is a therapeutic alternative to 
mitral valve (MV) surgery in symptomatic patients with moderate to severe MR at prohibitive 
surgical risk [1–3]. TMVR with the MitraClip procedure can be successfully performed in 
patients with secondary MR (sMR) and primary MR (pMR) if mitral valve (MV) anatomy is 
suitable [4]. Its clinical efficacy and safety have been proven in a large number of patients [4–
6]. 
Acute procedural success rates are reported to be up to 99% and are followed by 
symptomatic improvement in about 80% of cases [7]. 
A high baseline systolic pulmonary artery pressure (sPAP), a mean elevated baseline 
mitral valve gradient (MVG), concomitant chronic kidney disease, anemia, peripheral artery 
disease, and tricuspid regurgitation have been previously reported as independent predictors 
of poor short-term outcomes after MitraClip procedures [8, 9, 11]. 
Although more than 70,000 patients have undergone MitraClip procedures to date, 
data on long-term outcome and durability of MR reduction are limited, and parameters 
predicting adverse long-term outcomes are not well defined. 
The objectives of the present study were to evaluate functional and echocardiographic 
long-term outcomes 5 years subsequent to transcatheter edge-to-edge mitral valve repair with 
the MitraClip procedure in a single high-volume center and assess predictors of poor 
outcomes. 
 
 3 
METHODS 
Patients and endpoints 
In this single-center study, consecutive patients undergoing TMVR with the MitraClip 
system were prospectively included. From February 2011 to February 2014 symptomatic 
(functional New York Heart Association [NYHA] class > II), and surgical high-risk patients 
with moderate-to-severe MR were evaluated for TMVR. All patients underwent TMVR 
following heart team judgement according to surgical high-risk (EuroSCORE II > 6%).  
All patients underwent clinical and echocardiographic examinations before and 5 years 
after the MitraClip procedure. 
According to Mitral Valve Academic Research Consortium (MVARC) definitions, the 
primary endpoint was defined as all-cause mortality [24]. The secondary endpoint was an 
improvement in functional capacity: functional NYHA class at follow-up was < II; 25% 
amelioration in exercise capacity (six-minute walking test [6MWT]).  
The study was authorized by the local ethics committee and in accordance with the 
Declaration of Helsinki. All patients signed written, informed consent before study inclusion. 
 
Echocardiography and follow-up assessment 
Echocardiographic assessment before and after TMVR was done following current 
recommendations and guidelines which included a comprehensive echocardiography [4, 12]. 
The severity of MR was graded using the radius of proximal isovelocity surface area (PISA 
radius), effective regurgitant orifice area (EROA), as well as vena contracta (VC) width and 
regurgitant volume. EROA and regurgitation volume were calculated using the semi-
quantitative PISA-method [13]. The echocardiographic studies were performed with a 
commercially available echocardiographic system (iE 33, Philips Medical Systems, Andover, 
Massachusetts) and echocardiography probes (X5-1, X7-2t) allowing acquisition of two- (2D) 
and three-dimensional (3D) data sets. sPAP was estimated from Doppler-based peak tricuspid 
regurgitation velocity according to use of modified Bernoulli equation (Delta-pressure: 4 × 
velocity) to approximate differences of pressure between right ventricle and atrium.  
The echocardiographer who performed follow-up evaluation was blinded to 
procedural outcomes and patient characteristics. Trained personnel carried out clinical follow-
up evaluation, unattended by the interventionalists or procedural echocardiographer. 
 
Interventional edge-to-edge repair of MR  
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Procedural details of TMVR with the MitraClip system have been described 
previously [14, 15]. During the MitraClip procedure, acute changes of MR severity were 
assessed by intraprocedural transesophageal echocardiography as supposed by Foster and 
Wunderlich [16, 17]. Acute procedural success was defined as a reduction of MR by at least 
one grade having a residual MR < 2+. The number of clips required for procedural success 
was left to the discretion of the treating physician. Before clip release, echocardiography was 
performed to exclude clinically relevant MV stenosis (mean valve gradient [MVG] > 5 
mmHg).  
 
Statistical analysis 
Normal distribution of continuous variables was examined using the Kolmogorov–
Smirnov test. Continuous data were expressed as mean values ± standard deviation. The 
Student two-sample t-test or Man-Whitney-U test was performed to compare continuous 
variables. The Fisher exact test or χ2 test was used to compare categorical data. Two-tailed p-
values were considered to be significant if ranging below 0.05. Univariate analysis was 
performed to assess the impact of etiology of MR on clinical outcomes. The predictors of 5-
year mortality were estimated employing the Cox proportional regression analysis. Survival 
and cumulative incidence of re-do in groups were compared using the log-rank test and were 
estimated with the Kaplan–Meier curve. The regression and receiver operating characteristic 
(ROC) analysis were performed to determine independent predictors with cut-off values of 
functional outcomes and mortality. 
Statistics were performed using SPSS for Windows (PASW statistic, Version 20.0.0.0, 
SPSS Inc., Chicago, Illinois, USA).  
 
RESULTS 
Baseline data and procedural outcomes 
Two hundred sixty-five consecutive, surgically high-risk patients (81.4 ± 8.1 years, 
46.7% female, Logistic EuroSCORE: 19.7 ± 16.7%, 60.5% sMR) underwent TMVR with the 
MitraClip system, and the majority of patients (88%, n = 233) completed a 5-year follow-up 
including physical, laboratory and echocardiographical examinations. Patients lost to follow-
up (n = 32) were contacted concerning life quality, complaints and hospitalization via 
telephone. 
The baseline characteristics are presented in Table 1. There were no differences 
between the groups in demographic baseline characteristics. However, at baseline, patients 
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with sMR presented worse functional capacity (6MWT: 253.3 ± 107.7 m vs. 267.1 ± 160.2 m; 
p = 0.2; NYHA > III 44.2% vs. 13.8%; p = 0.06) compared to patients with pMR.  
The procedure was successfully performed in 242 (91.3%) patients with implantation 
of more than one clip in 32% of cases. Six MitraClip procedures were aborted due to relevant 
MV stenosis (MVG > 5 mmHg) after clip closure. Four of those patients were treated for 
pMR. 13 procedures were aborted due to irreducible MR.  
Of note, there was no procedural-related mortality, ten patients (23.8%) had minor 
bleeding, and one patient had pericardial tamponade, which could be effectively treated with 
pericardiocentesis. All acute complications could be successfully managed before discharge. 
Overall, interventional failure rates were low, however, patients with pMR showed 
statistically significant higher interventional failure rates (pMR: 8.6%, sMR: 3.1%; p = 0.04).  
During 5-year follow-up 3 patients underwent surgery for recurrent MR (pMR: 1,9%, 
sMR: 0.6%; p = 0.3), 16 patients required a second clipping (sMR: 6.8%, pMR: 4.7%, p = 
0.5) and 4 patients were treated with additional catheter-based approaches (Carillon®, Cardiac 
Dimension, Kirkland, The USA; Cardioband®, Edwards Lifesciences, United Kingdom) due 
to recurrent severe MR and decompensated heart failure (sMR: 1.8%, pMR: 0.9%, p = 0.6) 
(Supplementary materials, Suppl. Fig. 4). 
 
Echocardiographic measures at baseline and five-year follow-up 
Concerning baseline echocardiographic characteristics, there were no significant 
differences between sMR and pMR in MR defining parameters and sPAP. Patients with sMR 
had larger baseline LV volumes (LVEDV: 165.3 ± 62.6 mL, 135.8 ± 49.2 mL; p = 0.03; 
LVESV: 106.4 ± 53.3 mL, 59.3 ± 36.6 mL; p = 0.001) and significantly impaired baseline left 
ventricle (LV) systolic function (38.3 ± 14.1%, 58.1 ± 15%; p = 0.0001). Patients with sMR 
showed impaired right ventricle (RV) function at baseline as well (TAPSE: 1.7 ± 0.4 cm, 2 ± 
0.2 cm; p = 0.09) (Table 2). 
At 5-year follow-up  a sustained reduction of MR (MR ≤ 2) was found in 74% of 
patients (sMR: 77%, pMR: 71.5%; p = 0.9). There were no significant changes in LV 
volumes (LVEDVsMR: 162.4 ± 56.7 mL, 154.5 ± 66.9 mL; p = 0.5; LVEDVpMR: 127.8 ± 47.3 
mL, 116.6 ± 26.4 mL; p = 0.3; LVESVsMR: 105.2 ± 45.5 mL, 99.6 ± 57.8 mL; p = 0.6; 
LVESVpMR: 56.2 ± 34.5 mL, 51.6 ± 20.2 mL; p = 0.5). Left ventricular ejection fraction 
(LVEF) was not significantly changed 5 years after the MitraClip procedure (EFsMR 36.9  
12.6%, 38.7  13.6%, p = 0.5; EFpMR 58.1  12.2%, 58.4  9.7%, p = 0.9). In sMR patients, 
sPAP was significantly reduced at follow-up (50 ± 17.4 mmHg, 39.3 ± 17.3 mmHg, p = 0.05), 
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however, not significantly in pMR patients (49.4 ± 18.3 mmHg; 41.6 ± 18.7 mmHg, p = 0.3) 
(Table 3). RV function increased significantly just in patients with sMR (1.7 ± 0.4 cm, 1.9 ± 
0.4 cm, p = 0.03; 2 ± 0.2 cm, 2.1 ± 0.4 cm, p = 0.5). MVG significantly increased after 
MitraClip procedures (1.4 ± 0.8 mmHg, 3.5 ± 2.9 mmHg; p = 0.001) without incidence of 
clinically relevant MV stenosis.  
 
Clinical outcomes and predictors of outcome 
At 5-year follow-up the majority of patients (65.4%) presented with improved heart 
failure related symptoms (functional NYHA class  II) and improved exercise tolerance 
(6MWT: 243.8 ± 121.3 m, 298.1 ± 118.6 m; p = 0.04). The functional capacity at follow-up 
did not differ between the groups (NYHA > II sMR: 34.6%, pMR 33.3%; p = 0.6) (Fig. 2). 
However, functional amelioration was more pronounced in sMR patients as assessed by 
functional NYHA class (sMR: 3.5 ± 0.5, 2.1 ± 0.9, p = 0.0001; pMR: 3.2 ± 0.4, 2.2 ± 1; p = 
0.04) and 6MWT (sMR: 235.3 ± 107.7 m, 305.3 ± 123.1 m; p = 0.03; pMR: 267.1 ± 160.2 m, 
278.6 ± 111.9 m; p = 0.8). Decreased levels of N-terminal pro-B-type natriuretic peptide were 
documented in both groups (sMR: 7635.3 ± 13639.8 pg/mL, 3943.4 ± 4190.5 pg/mL; p = 
0.01; pMR: 7157.2 ± 10920 pg/mL, 4313.7 ± 7574.8 pg/mL; p = 0.02) (Table 3). 
All-cause mortality was 16% at 5-year follow-up and was significantly higher in 
patients with sMR (sMR: 19%, pMR: 10%; p = 0.05) (Supplementary materials, Table 1, 
Fig. 3).  
According to ROC analysis baseline sPAP > 45 mmHg, baseline MVG > 1.5 mmHg 
and baseline level of creatinine > 2 mg/dL were found to be independent predictors for all-
cause mortality at 5-year follow-up. Furthermore, baseline level of creatinine (cut-off 
value:1.33 mg/dL; HR: 0.695), baseline sPAP (cut-off value: 50 mmHg; HR: 0.96) and 
baseline MVG (cut-off value: 1.4 mmHg; HR: 0.82) were used as independent predictors for 
poor functional outcomes at 5-year follow-up (Supplementary materials, Figs. 1, 2).  
 
DISCUSSION 
The main findings of the present study are as follows: (1) Acute procedural failure was 
higher in pMR patients. (2) A majority of patients (74%) showed sustained MR reduction, 
increased RV function and reduced sPAP at 5-year follow-up. (3) Despite pronounced clinical 
and echocardiographic amelioration at follow-up and lower interventional failure rates, all-
cause 5-year mortality was significantly higher in sMR patients. Baseline levels of creatinine 
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> 2 mg/dL, MVG > 1.5 mmHg and sPAP > 50 mmHg were independent predictors of the 5-
year mortality and poor functional outcomes.  
 
Survival and re-intervention rates 
Mortality after TMVR with the MitraClip device has been evaluated previously in 
different studies. Toggweiler et al. [18] found in 75 patients, a patient mortality of 4% at 30 
days, 9% at 1 year and 25% (sMR: 28%, pMR 18%) at 2 years after the MitraClip procedure. 
Comparable data were presented in 304 patients by Capodanno et al. [19] (4% at 30 days, 
11% at 1-year, and 19% at 2-years). The EVEREST II study found a 20% 5-year mortality 
without statistical difference between MR etiologies [6].  
In line with those studies, sustained MR reduction was found with improved 
functional capacity and quality of life 5 years after the MitraClip procedure. Although the 
patients in the present study were considerably older (mean age: 81 years), they had sMR 
more often and were in higher baseline functional NYHA classes, long-term mortality rates 
(16%) were comparable to the cited studies. In contrast to EVEREST II, higher mortality in 
patients with sMR was found despite noticeable improvement of functional capacity at 
follow-up. Of note, in the early EVEREST studies, echocardiographic feasibility criteria were 
far more restrictive, and the majority of patients were treated for pMR, which might account 
for different acute and long-term procedural success rates.  
Higher all-cause mortality at follow-up in sMR patients was found, and might be 
explained by the advanced age of sMR patients, a more impaired baseline LV and RV 
function compared to pMR patients. Similar findings were presented in the COAPT 
(Cardiovascular Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients 
with Functional Mitral Regurgitation) trial. In this trial, Stone et al. found 29.1% 2-year 
mortality in 302 patients with sMR despite being younger patients, was relevantly higher than 
the present collective. This might be explained through the present findings “predictors of 
mortality” such as impaired baseline renal function (creatinine clearance < 51 mL/min), 
advanced systolic heart failure (LVEF 31%), and elevated RV systolic pressure (> 44 mmHg) 
[25].  
Buzzatti et al. [26] showed higher 5-year mortality (about 50%) with good mid-term 
results including reduction of MR and improved symptoms in 339 patients with relevant MR. 
In line with current results, they found pronouncedly worse outcomes and higher mortality in 
patients with secondary MR associated with worse LV remodelling and function.   
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Predictors of adverse outcome 
Azzalini et al. [22] showed that an impaired LV function was associated with 
increased mortality in 77 patients with sMR one year after the MitraClip procedure. This 
finding is in line with the present data.  A higher 5-year mortality in sMR patients with 
reduced baseline LV function was found (EF < 40%) compared to pMR patients with a 
baseline LVEF > 55%. 
Another independent marker for secondary endpoint was the baseline level of 
creatinine (> 2 mg/dL) in the current study. This finding is supported by a study from Ohno et 
al. [23]. They found a significant adverse effect of concomitant chronic kidney disease on MR 
reduction, functional capacity (functional NYHA class), survival and frequency of re-repair in 
214 patients with severe MR 1 year after the MitraClip procedure.  
Toggweiler [9] (baseline MVG > 3 mmHg) and Neuss et al. (post-procedural MVG > 
5 mmHg) showed a devastating impact of higher MVG on clinical outcomes and procedural 
success [18]. In concordance with those results, baseline MVG (> 1.5 mmHg) as an 
independent predictor for both primary and secondary endpoints at 5-year follow-up was 
found in the present study.  
Moreover, Matsumoto et al. [11] found that pre-existing pulmonary hypertension was 
a strong predictor of higher all-cause mortality 12 months after the MitraClip procedure. The 
Association between worse outcomes and advanced heart disease and symptoms have been 
presented by Buzzatti et al. [26] in more than 300 patients with relevant MR at 5-year follow-
up. The cited study validates present findings; elevated baseline sPAP values are an 
independent predictor of (> 45 mmHg) adverse outcomes and (> 50 mmHg) all-cause 
mortality at 5-year follow-up.  
 
Limitations of the study 
This single-center retrospective study has several limitations. Data was reported from 
a single-center experience, and all echocardiographic analyses were not verified by an 
independent core lab. Furthermore, the 5-year follow-up was sufficiently completed in 233 
(88%) patients. Because of this, the present results should be proven in multi-center studies 
with a larger patient collective.  
 
CONCLUSIONS 
  Transcatheter mitral valve repair with MitraClip procedure was found to be safe, cause 
sustained MR reduction, and increase RV function during 5 years subsequent to the 
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procedure. Despite pronounced functional and echocardiographical amelioration and lower 
procedural failure, sMR patients showed a higher all-cause 5-year mortality compared to 
patients with pMR. Elevated baseline creatinine, baseline levels of MVG and baseline sPAP 
were associated with poor functional outcome and high all-cause 5-year mortality. 
 
Conflict of interest: None declared 
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Table 1. Baseline demographical characteristics 
 
 
sMR — secondary mitral regurgitation; pMR — primary mitral regurgitation; BMI — body mass index; NYHA 
— New York Heart Association functional classification 
 
 
 
 
 
 
All patients 
(n = 265) 
sMR (n = 160) pMR (n = 105) P 
Gender (female) 46.7% 40.9% 56.7% 0.1 
Age [years] 81.4 ± 8.1 79.1 ± 8.7 84.6 ± 5.7 0.1 
BMI [kg/m2] 25.4 ± 4.2 26 ± 4.6 24.5 ± 3.4 0.1 
EuroScore [%] 19.7 ± 16.7 21.4 ± 17.5 16.9 ± 15.2 0.3 
NYHA ≥ II 100% 100% 100% 1 
NYHA III 68.1% 55.8% 86.2%  
NYHA IV 31.9% 44.2% 13.8% 0.06 
Chronic heart failure 70.7% 81.4% 66.7% 0.1 
Coronary heart diesease 71.4% 75.9% 65% 0.3 
Arterial hypertension 66.7% 70.5% 61.3% 0.3 
History of stroke 4% 2.3% 6.5% 0.4 
Peripheral artery diesease  10.7% 11.4% 9.7% 0.6 
Diabetes mellitus  34.7% 45.5% 29.4% 0.09 
Hyperlipidemia  36% 45.5% 31.6% 0.1 
Nicotine  24% 25% 22.6% 0.5 
Creatinine [mg/dL] 1.5 ± 0.8 1.6 ± 0.9 1.4 ± 0.7 0.2 
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Table 2: Baseline echocardiographical characteristics 
 
sMR — secondary mitral regurgitation; pMR — primary mitral regurgitation; LVEDV — left ventricular end-
diastolic volume; LVESV — left ventricular end-systolic volume; LVEF — left ventricular ejection fraction; 
MV — mitral valve: MR — mitral regurgitation; PISA — proximal isovelocity surface area; VC — vena 
contracta; EROA — effective regurgitant orifice area; TAPSE — tricuspid annular systolic excursion  
 
 
Table 3. Echocardiographical and clinical outcomes at follow-up 
 Baseline Follow-up P 
LVEDV [mL] 
sMR 
pMR 
150 ± 55.5 
162.4 ± 56.7 
127.8 ± 47.3 
140.9 ± 58.4 
154.5 ± 66.9 
116.5 ± 26.4 
0.3 
0.5 
0.3 
LVESV [mL] 
sMR 
pMR 
87.6 ± 47.7 
105.2 ± 45.5 
56.2 ± 34.5 
82.4 ± 52.8 
99.6 ± 57.8 
51.6 ± 20.2 
0.4 
0.6 
0.5 
LVEF [%] 
sMR 
pMR 
44.5 ± 16.1 
36.9 ± 12.6 
58.1 ± 12.2 
45.8 ± 15.5 
38.7 ± 13.6 
58.4 ± 9.7 
0.5 
0.5 
0.9 
IVSDD [cm] 
sMR 
pMR 
1.2 ± 0.3 
1.2 ± 0.3 
1.3 ± 0.3 
1 ± 0.2 
1 ± 0.2 
1.2 ± 0.3 
0.04 
0.04 
0.3 
MR  
sMR 
pMR 
3.1 ± 0.4 
3 ± 0.3 
3.4 ± 0.5 
1.7 ± 0.5 
1.6 ± 0.5 
2 ± 0.4 
0.0001 
0.0001 
0.0001 
 All patients 
n=265) 
sMR (n = 160) pMR (n = 105) P 
LVEDV [mL] 154.4 ± 59 165.3 ± 62.6 135.8 ± 49.2 0.03 
LVESV [mL] 87.3 ± 52.4 106.4 ± 53.3 59.3 ± 36.6 0.0001 
LVEF [%] 46.3 ± 17.4 38.3 ± 14.1 58.1 ± 15 0.0001 
sPAP [mmHg] 47.5 ± 15 46.2 ± 15.7 50 ± 14 0.4 
MV gradient [mmHg] 1.6 ± 0.9 1.4 ± 0.8 1.8 ± 1 0.03 
MR 3.2 ± 0.4 3.1 ± 0.3 3.4 ± 0.5 0.1 
MR grade III 79.7% 90.9% 63.3% 0.02 
MR grade IV 18.9% 6.8% 36.7% 0.03 
E/A ratio 2.4 ± 1 2.6 ± 1.2 2.2 ± 0.8 0.2 
PISA radius [cm] 0.9 ± 0.2 0.8 ± 0.2 0.9 ± 0.3 0.2 
VC width [cm] 1.4 ± 4.4 1.5 ± 5.3 1.2 ± 2.3 0.7 
EROA [cm2] 0.6 ± 0.3 0.5 ± 0.1 0.6 ± 0.4 0.3 
Regurgitation volume [mL] 54.4 ± 16 53.2 ± 16 56.3 ± 16.2 0.4 
Tricuspid regurgitation 2.1 ± 0.8 2.1 ± 0.8 2 ± 0.8 0.6 
TAPSE [cm] 1.8 ± 0.4 1.7 ± 0.4 2 ± 0.2 0.09 
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MR ≤ II [%] 
sMR 
pMR 
0 
0 
0 
97.4 
100 
92.9 
0.0001 
0.0001 
0.0001 
MR > II [%] 
sMR 
pMR 
100 
100 
100 
2.6 
0 
7.1 
0.0001 
0.0001 
0.0001 
Mitral gradient [mmHg] 
sMR 
pMR 
1.4 ± 0.8 
1.4 ± 0.8 
1.5 ± 0.9 
3.5 ± 2.9 
2.8 ± 1.3 
4.8 ± 4.5 
0.0001 
0.0001 
0.02 
TAPSE [cm] 
sMR: 
pMR: 
1.8 ± 0.3 
1.7 ± 0.4 
2 ± 0.2 
1.9 ± 0.4 
1.9 ± 0.4 
2.1 ± 0.4 
0.008 
0.03 
0.5 
sPAP [mmHg] 
sMR 
pMR 
49.7 ± 17.3 
50 ± 17.4 
49.4 ± 18.3 
40.7 ± 17.5 
39.3 ± 17.3 
41.6 ± 18.7 
0.02 
0.05 
0.3 
Functional NYHA class 
sMR 
pMR 
3.4 ± 0.5 
3.5 ± 0.5 
3.2 ± 0.4 
2.2 ± 0.9 
2.1 ± 0.9 
2.2 ± 1 
0.0001 
0.0001 
0.004 
6MWT [m] 
sMR 
pMR 
243.8 ± 121.3 
235.3 ± 107.7 
267.1 ± 160.2 
298.1 ± 118.6 
305.3 ± 123.1 
278.6 ± 111.9 
0.04 
0.03 
0.8 
NT-proBNP [pg/mL] 
sMR 
pMR 
5987.3 ± 9989.3 
3844.7 ± 3099.4 
10510.6 ± 16770.4 
4614.7 ± 5596.6 
4581.1 ± 4356.1 
4685.8 ± 7939.8 
0.5 
0.2 
0.4 
sMR — secondary mitral regurgitation; pMR — primary mitral regurgitation; LVEDV — left ventricular end-
diastolic volume; LVESV — left ventricular end-systolic volume; LVEF — left ventricular ejection fraction; 
IVSDD — diastolic interventricular septum diameter; MR — mitral regurgitation; TAPSE — tricuspid annular 
systolic excursion; sPAP — systolic pulmonary artery pressure; NYHA — New York Heart Association; 6MWT 
— 6 minute walk test; NTpro-BNP — N-terminal pro-B-type natriuretic peptide 
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Figure 1. Changes in functional New York Heart Association (NYHA) class; pMR — 
primary mitral regurgitation; sMR — secondary mitral regurgitation. 
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Figure 2: Reduction of mitral regurgitation (MR) at 5-year follow-up; pMR — primary mitral 
regurgitation; sMR — secondary mitral regurgitation. 
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